Publikationen, an denen er mitarbeitet José Alejandro Pérez Fidalgo (26)

2019

  1. A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients

    Clinical Epigenetics, Vol. 11, Núm. 1

  2. Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904)

    Clinical Cancer Research

2018

  1. Multicenter phase II study of lurbinectedin in BRCAMutated and unselected metastatic advanced breast cancer and biomarker assessment substudy

    Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3134-3143

2017

  1. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation

    Cell Metabolism, Vol. 26, Núm. 4, pp. 633-647.e7

2016

  1. Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 160, Núm. 1, pp. 69-77

  2. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

    Critical Reviews in Oncology/Hematology, Vol. 97, pp. 96-106

2014

  1. Breast cancer stem cells

    Stem Cells in Cancer: Should We Believe or Not? (Springer Netherlands), pp. 107-126

  2. Concordance of genomic alterations between primary and recurrent breast cancer

    Molecular Cancer Therapeutics, Vol. 13, Núm. 5, pp. 1382-1389

  3. Emerging EGFR antagonists for breast cancer

    Expert Opinion on Emerging Drugs, Vol. 19, Núm. 2, pp. 165-181

  4. MicroRNA profile in very young women with breast cancer

    BMC Cancer, Vol. 14, Núm. 1

  5. New era in the fight against cancer: evolution and cancer: progress in tumor treatments

    Mètode Science Studies Journal: Annual Review, Núm. 4, pp. 100-105

  6. Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 9, pp. 814-822

  7. Zoledronic acid in the treatment of metastatic breast cancer

    Anti-Cancer Drugs, Vol. 25, Núm. 1, pp. 1-7

2013

  1. An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer

    Breast, Vol. 22, Núm. 5, pp. 974-979

  2. Nova era en el combat contra el càncer: evolució i càncer: progrés i tractament de tumors

    Mètode: Revista de difusió de la investigació, Núm. 78, pp. 82-87

  3. Nueva era en el combate contra el cáncer: evolución y cáncer: progreso y tratamiento de tumores

    Mètode: Revista de difusión de la Investigación, Núm. 78, pp. 74-81

2012

  1. Antiangiogenesis in hormone-refractory breast cancer

    Cancer and Chemotherapy Reviews, Vol. 7, Núm. 1, pp. 12-23

  2. Integrating radical local treatment of the primary in the management of stage IV breast cancer. When is the best moment for the resection of the primary tumor?

    European Journal of Surgical Oncology

  3. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways

    Cancer Treatment Reviews, Vol. 38, Núm. 6, pp. 698-707

2011

  1. Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?

    Breast, Vol. 20, Núm. 6, pp. 548-554